GCUK Patient Meetings - 2022 Video Reports
Liverpool Meeting - October 2022
Speakers
Dr Nasim Ali - Managing GISTs
What is a GIST and how is it treated? (0:52). Why go to a specialist centre? (03:15). Risk of recurrence: size, mitotic count, location (04:45). Metastasis and treatment where surgery is difficult (7:38). Imatinib: how it works and side-effects (09:45). Sunitinib (15:30). Regorafinib (16:45). Repretinib (17:30). Avapritinib (16:45). Other therapies (20:30). Neoadjuvant treatment (23:20). Risk of progressive disease (25:00). Why specialist teams are important (25:40). PAWS-GIST – SIRT treatment (30:00).
Fiona McRonald - Molecular Testing in GISTS
Importance of molecular data. National Cancer Registry and what it does (01:00). Incidence of GISTS (3:25). Cells and Genes (5:11). The Human Genome and variations in DNA and cell type (7:35). Why do some cells become cancerous? advantageous and disadvantageous mutations (11:54). Treating cancer (15:40). KIT mutations (17:15). GIST molecular testing (21:10). Mutational variations (27:00)
Jim Watson - Managing relationships: A patient's perspective
There was a combined Q&A session
DR Nasim Ali – Managing a GIST: Where are we up to now?
Fiona McRanald – The Science behind why we do molecular testing
Jim Watson – A Patient’s Perspective
Q&A Session – Nic Puntis
GCUK Patient Meetings - 2022 Video Reports
Bath Meeting - March 2022
Speakers
Dr Sadaf Haque GP and Cancer lead for Gloucestershire - GIST Cancer UK's Introducing the educational video for GP's and Primary Care Clinicians: "Diagnosing GIST". This has been designed to raise awareness and a better understanding of the possible presentation of GIST amongst GPs.
Introduction to putting the resource together (0:00). The video and introduction to GISTs (8:00). Symptoms and diagnosis (10:05). Role of Specialist Centres (12:35). Possible treatments including imatinib (16:45). Prognosis for those with GISTs (18:15). Quality of life post diagnosis (19:30). Side-effects of surgery and treatment (22:30). Indicators of the likelihood of return (26:45). Monitoring of GIST patients by GPs (27:50). Involvement in trials (29:00).
- Chief Scientific Officer & Founding Director of RareCan - Professor Andy Hall, engaged with our audience to give an illuminating presentation on "Patient driven research".
- Consultant Oncologist - Dr Ramesh Bulusu and Sarcoma Specialist Pharmacist, Laura Ferro Lopez discussed "Generic Imatinib - Facts & Myths"
- Jayne Bressington GCUK Vice Chair & Patient Director PAWS-GIST presented an Update of GCUK activities since October 2021.